Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 14/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027182 | 0.93 | ACLY (0.39) | ALDH1A1MEN1MAPK1KMT2AACLY | |
| Benzene SCHEMBL5016963 | 0.90 | KMT2A (0.42) | ALDH1A1MEN1MAPK1KMT2ACCR2 | |
| SCHEMBL5027363 | 0.84 | KDM4E (0.39) | ALDH1A1MEN1KMT2AACLYKDM4E | |
| Benzene SCHEMBL5023466 | 0.82 | FLT1 (0.39) | ALDH1A1MEN1MAPK1KMT2ACCR2 | |
| SCHEMBL5023088 | 0.82 | KMT2A (0.43) | ALDH1A1MEN1MAPK1KMT2ACCR2 | |
| SCHEMBL5016928 | 0.81 | HSD17B10 (0.42) | ALDH1A1MEN1MAPK1KMT2AKDM4E | |
| SCHEMBL27678046 | 0.79 | KDM4E (0.37) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL27677756 | 0.77 | KMT2A (0.35) | ALDH1A1MEN1MAPK1KMT2AKDM4E | |
| SCHEMBL5022953 | 0.77 | KDM4E (0.53) | ALDH1A1MEN1MAPK1KMT2AKDM4E | |
| SCHEMBL5023519 | 0.76 | KDM4E (0.42) | ALDH1A1MEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | claimed |
| US-20070021478-A1 | Benzothiazolyl derivatives | NETTEKOVEN MATTHIAS H | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021478-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | ALDH1A1 716/4885MEN1 2848/4885MAPK1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.